Dendritic cell-mediated presentation of tumor-associated antigens

Dendritic cells (DCs) are specialized antigen-presenting cells essential for initiating adaptive immune responses against tumors. They capture tumor-associated antigens within the tumor microenvironment through phagocytosis of apoptotic or necrotic cancer cells. Upon maturation, DCs upregulate major histocompatibility complex (MHC) class I and II molecules and costimulatory proteins such as CD80, CD86, and CD40. Mature DCs migrate from the tumor site to lymphoid organs where they present processed peptide fragments on MHC molecules to naïve T-cells—activating cytotoxic CD8+ T-cells via cross-presentation on MHC-I and helper CD4+ T-cells via MHC-II[1][2][3][4]. This process is central in anti-tumor immunity; effective stimulation by DCs correlates with improved patient outcomes in cancer. Dysfunctional or immature DCs within tumors can impair anti-tumor responses. Therapeutic strategies such as dendritic cell vaccines aim to harness this pathway by loading patient-derived DCs with tumor neoantigens ex vivo before re-infusion[1]. However, "immune system stimulation via presentation of tumor-associated antigens by activated dendritic cells" describes an immunological mechanism rather than a discrete molecular entity.\n\nNotes:\n\nThe provided name refers **not** to an individual molecule/receptor but rather describes an important cellular immunological process involving multiple proteins (e.g., MHC-I/II), receptors (e.g., CCR7), costimulatory molecules (CD80/CD86), and entire cellular pathways[1][2][3][4]. Therefore:\n\n– It is **not** considered a canonical therapeutic target like an enzyme or receptor.\n– The entry should be flagged as incorrect for structured databases seeking single-molecule targets.\n– For structured data extraction purposes, consider mapping references instead directly onto key components such as “Major histocompatibility complex class I” or “Dendritic cell” if needed for granularity.\n\nIf you need information about one specific component involved in this pathway—such as “Major histocompatibility complex class I,” “CD80,” etc.—please specify so detailed structured data can be provided at the appropriate level.

Other names

Dendritic cell antigen presentationDC cross-presentation of tumor antigensTumor antigen presentation by dendritic cells